Evidence map›Paper›PMID 40883847›Full record

ArticleBiotechnology for biofuels and bioproducts2025

Pioneering microbial synthesis of gangliosides in the filamentous fungus Ashbya gossypii.

Javier F Montero-Bullón, Javier Martín-González, Rodrigo Ledesma-Amaro, Alberto Jiménez, Rubén M Buey

Abstract read
In one paragraph

Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Javier F Montero-BullónMetabolic Engineering Group. Department of Microbiology and Genetics, Universidad de Salamanca, Salamanca, Spain.
Javier Martín-GonzálezMetabolic Engineering Group. Department of Microbiology and Genetics, Universidad de Salamanca, Salamanca, Spain.
Rodrigo Ledesma-AmaroDepartment of Bioengineering and Imperial College Centre for Synthetic Biology, Imperial College London, London, UK.
Alberto JiménezMetabolic Engineering Group. Department of Microbiology and Genetics, Universidad de Salamanca, Salamanca, Spain.
Rubén M BueyMetabolic Engineering Group. Department of Microbiology and Genetics, Universidad de Salamanca, Salamanca, Spain. ruben.martinez@usal.es.

Funding

Ministerio de Ciencia e Innovación Juan de la Cierva, FJC2019-041035-IMinisterio de Ciencia e Innovación PID2023-150714OB-I00
6 · The paper itself

Abstract

Gangliosides are essential glycosphingolipids critical in neurodevelopment and cell signaling. Traditionally sourced from animal tissues, their production raises ethical concerns and faces challenges in scalability and cost. Chemoenzymatic methods have emerged as alternatives but lack flexibility and broad industrial applicability of microbial systems. However, complete microbial biosynthesis remains challenging due to the complexity of reconstructing the biosynthetic pathway in non-native hosts. We report the first successful complete microbial synthesis of gangliosides by engineering the industrial filamentous fungus Ashbya gossypii. Using modular metabolic engineering, we heterologously expressed human and yeast enzymes to reconstruct a functional ganglioside biosynthetic pathway. Pathways for producing activated N-acetylneuraminic acid, lactosylceramide, and sialylated intermediates were integrated, yielding GM3 and GD3 at milligram-per-liter levels. These titers were further enhanced by introducing a heterologous Leloir pathway for galactose metabolism. This work represents a foundational advance in microbial glycoengineering, offering a scalable, animal-free microbial platform for ganglioside production with broad applications.

Indexed as

Ashbya gossypiiGangliosidesMetabolic engineeringSphingolipids

Identifiers

PMID40883847
PMCPMC12395927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.